Table 1

Baseline characteristics (mean ± SD)

Sex male/female (n)

10/3

Age (year)

64 ± 6

Diabetes duration (year)

8 ± 5

Diabetic values at OGTT yes/no (n)

12/1

Lipid lowering drug (= statin) yes/no (n)

8/5

Drugs per day

4.3 ± 2.3

Anti-hypertensive drugs per day

1.5 ± 1.5

Beta-blocker yes/no (n)

4/9

Thiazide yes/no (n)

4/9

ACE-inhibitor yes/no (n)

5/8

Angiotensin-II receptor blocker yes/no (n)

4/9

Calcium channel blocker yes/no (n)

3/10

Anti-diabetic drugs per day

1.2 ± 0.9

Metformin yes/no (n)

9/4

Sulfonylurea yes/no (n)

3/10

Thiazolidinedione yes/no (n)

3/10

Metformin per day (mg)

1031 ± 864

HbA1C (%, Mono-S)

6.6 ± 0.6

Cholesterol (mmol/l)

4.4 ± 1.1

LDL (mmol/l)

2.9 ± 0.9

HDL (mmol/l)

1.28 ± 0.22

TG (mmol/l)

1.5 ± 0.7

CRP (mg/l)

2.4 ± 1.8

SBP (mmHg)

150 ± 21

DBP (mmHg)

83 ± 10

Height (cm)

171 ± 5

Weight (kg)

87 ± 17

BMI (kg/m2)

30 ± 7

Waist (cm)

103 ± 14

fP-glucose (mmol/l)

7.8 ± 1.2

fP-insulin (pmol/l)

98 ± 44

AUC glucose0–120 (mmol/l·min)

1607 ± 218

AUC glucose0–120 (mmol/l·min)1

667 ± 186

AUC insulin0–120 (nmol/l·min)

30 ± 12

AUC insulin0–120 (nmol/l·min)1

18 ± 8

ISI0,120 (mg·l2/mmol·mU·min)

40 ± 9

HOMA2 %B

65 ± 34

HOMA2 %S

59 ± 27

HOMA2 IR

2.0 ± 0.8


1stimulated secretion, area under curve at OGTT with value at 0 minutes as baseline.

Jönsson et al. Cardiovascular Diabetology 2009 8:35   doi:10.1186/1475-2840-8-35

Open Data